Faes Farma licences bilastines marketing rights in Indonesia to Kalbe

Spanish drugmaker Faes Farma has signed a licence agreement for the commercialization of its antihistamine bilastine (trade name Bilastina) in Indonesia with that country’s largest pharmaceutical firm Kalbe Pharma. Financial terms were not disclosed.

The Indonesian pharmaceutical market is one of the major emerging markets in Asia with annual growth rates between 12% and 15.5% during the last four years in a country with 230 million people, the companies noted.
Kalbe Pharma is the largest publicly listed pharmaceutical company in Southeast Asia leading the Indonesian pharmaceutical market with a share of 13% in prescription drugs and of 14% in over-the-counter products.
Bilastine is a latest generation antihistaminic, indicated for the symptomatic treatment of allergic rhinoconjuntivitis and urticaria, with a rapid onset, long- lasting action and a wide safety profile.

Current bilastine licensees